248 related articles for article (PubMed ID: 9873944)
1. New assays for the quality control of live oral poliovirus vaccine.
Furesz J; Levenbook I
Acta Microbiol Immunol Hung; 1998; 45(3-4):391-9. PubMed ID: 9873944
[TBL] [Abstract][Full Text] [Related]
2. Laboratory tests for live attenuated poliovirus vaccines.
Wood DJ; Macadam AJ
Biologicals; 1997 Mar; 25(1):3-15. PubMed ID: 9167004
[TBL] [Abstract][Full Text] [Related]
3. Neurovirulence.
Wood D
Dev Biol Stand; 1999; 101():127-9. PubMed ID: 10566785
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the new control methods for oral poliomyelitis vaccine.
Grachev VP; Karganova GG; Rumyantsev AA; Ivanova OE; Eremeeva TP; Drozdov SG
Dev Biol (Basel); 2001; 105():211-7. PubMed ID: 11763330
[TBL] [Abstract][Full Text] [Related]
5. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
[TBL] [Abstract][Full Text] [Related]
6. Development of a neurovirulent testing system for oral poliovirus vaccine with transgenic mice.
Levenbook I; Nomura T
Lab Anim Sci; 1997 Apr; 47(2):118-20. PubMed ID: 9150487
[TBL] [Abstract][Full Text] [Related]
7. Some aspects of the monkey neurovirulence test used for the assessment of oral poliovirus vaccines.
Furesz J; Contreras G
Dev Biol Stand; 1993; 78():61-70. PubMed ID: 8388832
[TBL] [Abstract][Full Text] [Related]
8. Transgenic mice as an alternative to monkeys for neurovirulence testing of live oral poliovirus vaccine: validation by a WHO collaborative study.
Dragunsky E; Nomura T; Karpinski K; Furesz J; Wood DJ; Pervikov Y; Abe S; Kurata T; Vanloocke O; Karganova G; Taffs R; Heath A; Ivshina A; Levenbook I
Bull World Health Organ; 2003; 81(4):251-60. PubMed ID: 12764491
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of new approaches to poliovirus vaccine neurovirulence tests.
Wood DJ
Dev Biol Stand; 1996; 86():79-83. PubMed ID: 8785995
[TBL] [Abstract][Full Text] [Related]
10. A poliovirus-susceptible transgenic mouse model as a possible replacement for the monkey neurovirulence test of oral poliovirus vaccine.
Dragunsky E; Taffs R; Chernokhvostova Y; Nomura T; Hioki K; Gardner D; Norwood L; Levenbook I
Biologicals; 1996 Jun; 24(2):77-86. PubMed ID: 8889053
[TBL] [Abstract][Full Text] [Related]
11. Estimation of the neurovirulence of poliovirus by non-radioisotope molecular analysis to quantify genomic changes.
Horie H; Tano Y; Doi Y; Hashizume S
Biologicals; 1998 Dec; 26(4):289-97. PubMed ID: 10403032
[TBL] [Abstract][Full Text] [Related]
12. Microevolution of type 3 Sabin strain of poliovirus in cell cultures and its implications for oral poliovirus vaccine quality control.
Rezapkin GV; Norwood LP; Taffs RE; Dragunsky EM; Levenbook IS; Chumakov KM
Virology; 1995 Aug; 211(2):377-84. PubMed ID: 7645242
[TBL] [Abstract][Full Text] [Related]
13. Neurovirulence test for oral live poliovaccines using poliovirus-sensitive transgenic mice.
Abe S; Ota Y; Koike S; Kurata T; Horie H; Nomura T; Hashizume S; Nomoto A
Virology; 1995 Feb; 206(2):1075-83. PubMed ID: 7856082
[TBL] [Abstract][Full Text] [Related]
14. Isolation of vaccine-derived type 1 polioviruses displaying similar properties to virulent wild strain Mahoney from sewage in Japan.
Horie H; Yoshida H; Matsuura K; Miyazawa M; Wakabayashi K; Nomoto A; Hashizume S
J Med Virol; 2002 Nov; 68(3):445-51. PubMed ID: 12226835
[TBL] [Abstract][Full Text] [Related]
15. Developments in the production and quality control of poliovirus vaccines -- historical perspectives.
Furesz J
Biologicals; 2006 Jun; 34(2):87-90. PubMed ID: 16621594
[TBL] [Abstract][Full Text] [Related]
16. Genetic stability of Sabin 1 strain of poliovirus: implications for quality control of oral poliovirus vaccine.
Rezapkin GV; Alexander W; Dragunsky E; Parker M; Pomeroy K; Asher DM; Chumakov KM
Virology; 1998 Jun; 245(2):183-7. PubMed ID: 9636357
[TBL] [Abstract][Full Text] [Related]
17. Studies on neurovirulence in poliovirus-sensitive transgenic mice and cynomolgus monkeys for the different temperature-sensitive viruses derived from the Sabin type 3 virus.
Abe S; Ota Y; Doi Y; Nomoto A; Nomura T; Chumakov KM; Hashizume S
Virology; 1995 Jun; 210(1):160-6. PubMed ID: 7793068
[TBL] [Abstract][Full Text] [Related]
18. Genetic stability and mutant selection in Sabin 2 strain of oral poliovirus vaccine grown under different cell culture conditions.
Taffs RE; Chumakov KM; Rezapkin GV; Lu Z; Douthitt M; Dragunsky EM; Levenbook IS
Virology; 1995 Jun; 209(2):366-73. PubMed ID: 7778271
[TBL] [Abstract][Full Text] [Related]
19. Development of candidates for new type 2 and type 3 oral poliovirus vaccines.
Kohara M; Abe S; Yoshioka I; Nomoto A
Dev Biol Stand; 1993; 78():141-8. PubMed ID: 8388824
[TBL] [Abstract][Full Text] [Related]
20. Oral poliovirus vaccine type 3 from a patient with transverse myelitis is neurovirulent in a transgenic mouse model.
Thorley B; Kelly H; Nishimura Y; Yoon YK; Brussen KA; Roberts J; Shimizu H
J Clin Virol; 2009 Apr; 44(4):268-71. PubMed ID: 19269246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
